Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Biofrontera ( (DE:B8FK) ).
Biofrontera AG reported its financial results for 2024, highlighting a significant sales growth in Europe and strategic partnerships to expand its product portfolio. Despite a decrease in US revenues and ongoing litigation expenses, the company remained EBITDA-positive in its core operations. The company anticipates continued revenue growth in Europe for 2025, with Germany as a key driver, and expects to return to profitability as litigation expenses have been provisioned.
More about Biofrontera
Biofrontera AG is an international biopharmaceutical company focused on dermatological products. The company is known for its product Ameluz®, which is used in photodynamic therapy, and has recently expanded its portfolio through partnerships with Leo Pharma GmbH and Galenica AB in key markets like Germany and the UK.
Technical Sentiment Signal: Buy
Current Market Cap: €14.95M
See more data about B8FK stock on TipRanks’ Stock Analysis page.